AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Interleukin-17F

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q96PD4

UPID:

IL17F_HUMAN

Alternative names:

Cytokine ML-1

Alternative UPACC:

Q96PD4; Q6NSI0; Q7Z6P4; Q96PI8; Q9NUE6

Background:

Interleukin-17F, also known as Cytokine ML-1, plays a pivotal role in the immune system. It is an effector cytokine of both innate and adaptive immunity, crucial for antimicrobial defense and tissue integrity. Through signaling pathways involving IL17RA-IL17RC and TRAF6, it activates NF-kappa-B and MAPkinase, leading to the production of cytokines, chemokines, and antimicrobial peptides.

Therapeutic significance:

Interleukin-17F is linked to familial Candidiasis, 6, a disorder marked by impaired clearance of fungal infections, particularly Candida. Its role in immune responses and inflammation highlights its potential as a target for therapeutic strategies in treating fungal infections and immune-related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.